194 related articles for article (PubMed ID: 15057264)
41. Attachment sites and neutralising epitopes of hepatitis B virus.
Glebe D
Minerva Gastroenterol Dietol; 2006 Mar; 52(1):3-21. PubMed ID: 16554703
[TBL] [Abstract][Full Text] [Related]
42. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes.
Meier A; Mehrle S; Weiss TS; Mier W; Urban S
Hepatology; 2013 Jul; 58(1):31-42. PubMed ID: 23213046
[TBL] [Abstract][Full Text] [Related]
43. Targeted gene transfer to nigrostriatal neurons in the rat brain by helper virus-free HSV-1 vector particles that contain either a chimeric HSV-1 glycoprotein C-GDNF or a gC-BDNF protein.
Wang X; Kong L; Zhang GR; Sun M; Geller AI
Brain Res Mol Brain Res; 2005 Sep; 139(1):88-102. PubMed ID: 15993510
[TBL] [Abstract][Full Text] [Related]
44. Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.
Grant KG; Krisky DM; Ataai MM; Glorioso JC
Biotechnol Bioeng; 2009 Mar; 102(4):1087-97. PubMed ID: 18828174
[TBL] [Abstract][Full Text] [Related]
45. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread.
Laquerre S; Argnani R; Anderson DB; Zucchini S; Manservigi R; Glorioso JC
J Virol; 1998 Jul; 72(7):6119-30. PubMed ID: 9621076
[TBL] [Abstract][Full Text] [Related]
46. Asialoglycoprotein receptor interacts with the preS1 domain of hepatitis B virus in vivo and in vitro.
Zhang X; Lin SM; Chen TY; Liu M; Ye F; Chen YR; Shi L; He YL; Wu LX; Zheng SQ; Zhao YR; Zhang SL
Arch Virol; 2011 Apr; 156(4):637-45. PubMed ID: 21207081
[TBL] [Abstract][Full Text] [Related]
47. Failure to complement infectivity of EBV and HSV-1 glycoprotein B (gB) deletion mutants with gBs from different human herpesvirus subfamilies.
Lee SK; Compton T; Longnecker R
Virology; 1997 Oct; 237(1):170-81. PubMed ID: 9344919
[TBL] [Abstract][Full Text] [Related]
48. The specific delivery of proteins to human liver cells by engineered bio-nanocapsules.
Yu D; Amano C; Fukuda T; Yamada T; Kuroda S; Tanizawa K; Kondo A; Ueda M; Yamada H; Tada H; Seno M
FEBS J; 2005 Jul; 272(14):3651-60. PubMed ID: 16008564
[TBL] [Abstract][Full Text] [Related]
49. Allele replacement: an application that permits rapid manipulation of herpes simplex virus type 1 genomes.
Horsburgh BC; Hubinette MM; Qiang D; MacDonald ML; Tufaro F
Gene Ther; 1999 May; 6(5):922-30. PubMed ID: 10505118
[TBL] [Abstract][Full Text] [Related]
50. Identification of the critical regions in hepatitis B virus preS required for its stability.
Lian M; Zhou X; Chen B; Li C; Gu X; Luo M; Zheng X
J Pept Sci; 2008 Mar; 14(3):307-12. PubMed ID: 17918766
[TBL] [Abstract][Full Text] [Related]
51. Calnexin associates with the precursors of glycoproteins B, C, and D of herpes simplex virus type 1.
Yamashita Y; Yamada M; Daikoku T; Yamada H; Tadauchi A; Tsurumi T; Nishiyama Y
Virology; 1996 Nov; 225(1):216-22. PubMed ID: 8918549
[TBL] [Abstract][Full Text] [Related]
52. Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons.
Müller L; Saydam O; Saeki Y; Heid I; Fraefel C
J Virol Methods; 2005 Jan; 123(1):65-72. PubMed ID: 15582700
[TBL] [Abstract][Full Text] [Related]
53. [Expression of HBV S and preS1 fusion gene in Pichia pastoris expression system].
Huang WJ; Wang YC; Zhang HY
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Dec; 19(4):366-9. PubMed ID: 16415997
[TBL] [Abstract][Full Text] [Related]
54. Liver cell-specific peptides derived from the preS1 domain of human hepatitis B virus.
Kang JH; Toita R; Asai D; Yamaoka T; Murata M
J Virol Methods; 2014 Jun; 201():20-3. PubMed ID: 24568971
[TBL] [Abstract][Full Text] [Related]
55. Broadly neutralizing anti-HBV antibody binds to non-epitope regions of preS1.
Chi SW; Kim J; Yi GS; Hong HJ; Ryu SE
FEBS Lett; 2009 Sep; 583(18):3095-100. PubMed ID: 19716826
[TBL] [Abstract][Full Text] [Related]
56. Transactivation of transforming growth factor alpha gene by hepatitis B virus preS1.
Ono M; Morisawa K; Nie J; Ota K; Taniguchi T; Saibara T; Onishi S
Cancer Res; 1998 May; 58(9):1813-6. PubMed ID: 9581818
[TBL] [Abstract][Full Text] [Related]
57. Identification of structural features of heparin required for inhibition of herpes simplex virus type 1 binding.
Herold BC; Gerber SI; Polonsky T; Belval BJ; Shaklee PN; Holme K
Virology; 1995 Feb; 206(2):1108-16. PubMed ID: 7856085
[TBL] [Abstract][Full Text] [Related]
58. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
Fu X; Tao L; Cai R; Prigge J; Zhang X
Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
[TBL] [Abstract][Full Text] [Related]
59. Heptad repeat 2 in herpes simplex virus 1 gH interacts with heptad repeat 1 and is critical for virus entry and fusion.
Gianni T; Piccoli A; Bertucci C; Campadelli-Fiume G
J Virol; 2006 Mar; 80(5):2216-24. PubMed ID: 16474129
[TBL] [Abstract][Full Text] [Related]
60. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
